cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Agus Prima
Contact Email
chairman@jsocmed.org
Phone
+6281269200232
Journal Mail Official
chairman@jsocmed.org
Editorial Address
Jl. DR. Wahidin Sudiro Husodo No.243B, Kembangan, Klangonan, Kec. Kebomas, Kabupaten Gresik, Jawa Timur 61124
Location
Kab. gresik,
Jawa timur
INDONESIA
The Journal of Society Medicine (JSOCMED)
Published by PT. CoinReads Media Prima
ISSN : -     EISSN : 29645565     DOI : https://doi.org/10.47353/jsocmed.v2i1
Core Subject : Health, Science,
Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience
The Journal of Society Medicine (JSOCMED) | ISSN (e): 2964-5565 is a leading voice in the Indonesia and internationally for medicine and healthcare. Published continuously, JSOCMED features scholarly comment and clinical research. JSOCMED is editorially independent from and its The Editor-in-Chief (EIC) is Prof. dr. Aznan Lelo, PhD, SpFK. JSOCMED offers many attractive features for authors, including free online access to all research articles, online publication ahead of print, and online responses to articles published as Quick Comments. In addition, as befitting a publication of the Journal of Society Medicine, JSOCMED implements best practice in scientific publishing with an open peer review process, declarations of competing interests and funding, full requirements for patient consent and ethical review, and statements of guarantorship, contributorship, and provenance.
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 4 Documents
 1 
Search results for , issue "Vol. 4 No. 12 (2025): December" : 4 Documents clear
Association of GWTG-HF Risk Score with Major Adverse Cardiovascular Events in Acute Heart Failure Patients: A Retrospective Study in a Tertiary Hospital in Indonesia Sumbayak, Novra Christy Grace; Hasan, Refli; Raynaldo, Abdul Halim; Haykal, Teuku Bob; Nasution, Ali Nafiah; Sarastri, Yuke
Journal of Society Medicine Vol. 4 No. 12 (2025): December
Publisher : CoinReads Media Prima

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.71197/jsocmed.v4i12.250

Abstract

Introduction: Heart failure (HF) affects approximately 64 million people globally, contributing to high mortality, morbidity, reduced quality of life, and substantial healthcare burden. Acute heart failure (AHF) requires urgent intervention and carries elevated risks of mortality and major adverse cardiovascular events (MACE). The Get With The Guidelines-Heart Failure (GWTG-HF) risk score, originally developed for predicting in-hospital mortality in HF patients, has shown potential in forecasting MACE in certain populations. However, its association with MACE in Indonesian AHF patients remains underexplored. Method: This retrospective observational cohort study included 319 AHF patients admitted to Adam Malik General Hospital, Medan, Indonesia, from January 2024 to March 2025. Patient characteristics, GWTG-HF scores, and in-hospital MACE were recorded. Statistical analyses involved receiver operating characteristic (ROC) curves and multivariate regression. Results: Patients had a mean age of 55 years, with 54.5% males. Median hospital stay was 5 days (range 1–47). Predominant features included acute decompensated HF (65.8%), infection as etiology (46.7%), HFrEF (52.0%), coronary heart disease (62.4%), and smoking (50.8%). In-hospital MACE occurred in 20.4% of patients, primarily mortality (18.8%), increasing with GWTG-HF risk categories (low: 8.1%; moderate: 17.4%; high: 36.7%). Age, systolic blood pressure, heart rate, sodium, and blood urea nitrogen significantly influenced MACE (p<0.05). The GWTG-HF score demonstrated good predictive performance for MACE (AUC 0.759, p<0.001; sensitivity 63.2%; specificity 78.1%). Conclusion: The GWTG-HF score is significantly associated with in-hospital MACE in Indonesian AHF patients, supporting its utility as a risk stratification tool to guide clinical decisions and optimize management.
Evaluation and Management of Suspected Sepsis and Septic Shock in Adult Patients Iwan , Azwar
Journal of Society Medicine Vol. 4 No. 12 (2025): December
Publisher : CoinReads Media Prima

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.71197/jsocmed.v4i12.251

Abstract

Introduction: Sepsis and septic shock represent critical medical emergencies with persistently high global mortality, ranging from 20% to 40% in severe cases. Prompt evaluation and early, time-sensitive management are essential to improve outcomes. This review highlights a pragmatic, evidence-based approach to the evaluation and management of suspected sepsis and septic shock in adults, aligned with current international guidelines and key clinical trials. Case Description: A 68-year-old man with a history of diabetes mellitus presented with fever, hypotension (mean arterial pressure 58 mmHg), tachycardia, and altered mental status. Laboratory investigations revealed leukocytosis and markedly elevated serum lactate levels (4.8 mmol/L). A urinary tract infection was identified as the potential source. Peripheral blood cultures were obtained from two sites prior to antimicrobial therapy. Broad-spectrum antibiotics (piperacillin–tazobactam and vancomycin) were initiated within 45 minutes, followed by resuscitation with 30 mL/kg balanced crystalloid solution. Persistent hypotension necessitated norepinephrine infusion, achieving a target mean arterial pressure ≥65 mmHg. Serial lactate monitoring guided ongoing resuscitation. Procalcitonin levels supported antibiotic de-escalation after seven days. The patient recovered without requiring organ support. Conclusion: Effective evaluation and management of suspected sepsis rely on early identification, rapid diagnostic assessment, prompt antimicrobial therapy, and timely hemodynamic resuscitation. Although early goal-directed therapy initially demonstrated benefit, contemporary trials indicate that individualized, high-quality usual care yields comparable outcomes in well-resourced settings. Procalcitonin-guided antibiotic stewardship may reduce treatment duration without adversely affecting survival. Early, tailored intervention remains pivotal in reducing sepsis-related mortality.
Biologic Therapies in Chronic Rhinosinusitis with Nasal Polyposis: Current Evidence and Future Perspectives Setiawan , Gunawan Wijaya
Journal of Society Medicine Vol. 4 No. 12 (2025): December
Publisher : CoinReads Media Prima

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.71197/jsocmed.v4i12.252

Abstract

Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a common type 2 inflammatory disease affecting approximately 1–4% of the population and is characterized by persistent nasal obstruction, olfactory dysfunction, facial pain, and substantial impairment in quality of life. Although standard therapies such as intranasal corticosteroids and endoscopic sinus surgery remain the mainstay of treatment, a significant proportion of patients experience recurrent or inadequately controlled disease. Improved understanding of the immunopathogenesis of CRSwNP has highlighted the central role of type 2 inflammation, driven by cytokines including interleukin-4, interleukin-5, interleukin-13, and immunoglobulin E, thereby enabling the development of targeted biologic therapies. Biologic agents such as dupilumab, mepolizumab, benralizumab, and omalizumab have demonstrated consistent efficacy in phase III randomized controlled trials and real-world studies, leading to significant reductions in nasal polyp burden, improvements in Sino-Nasal Outcome Test (SNOT-22) scores, restoration of olfactory function, and decreased need for systemic corticosteroids and revision surgery. Patient selection is increasingly guided by clinical phenotype and biomarkers, including blood eosinophil counts, total serum IgE levels, and the presence of comorbid asthma or aspirin-exacerbated respiratory disease. Emerging evidence supports the integration of biologic therapy with surgical management in refractory cases, while ongoing trials targeting upstream mediators such as interleukin-33 and thymic stromal lymphopoietin may further expand therapeutic options. Overall, biologic therapies represent a paradigm shift in the management of severe CRSwNP, paving the way toward precision-based, individualized treatment strategies.
Antidiabetic Effects of Moringa oleifera Leaf Extract on Blood Glucose Levels in Alloxan-Induced Diabetic Rats (Rattus norvegicus): A Systematic Literature Review Harahap , Armansyah Maulana; Ginting, Muhammad Aldi Rivai; Putri, Yulia; Sari, Herviani; Priawan, Indra
Journal of Society Medicine Vol. 4 No. 12 (2025): December
Publisher : CoinReads Media Prima

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.71197/jsocmed.v4i12.267

Abstract

Introduction: This systematic literature review, guided by PRISMA guidelines, evaluates the effectiveness of Moringa oleifera leaf extracts in reducing blood glucose levels in alloxan-induced diabetic rats. Method: Literature was searched in PubMed and Google Scholar using keywords including “Moringa oleifera,” “leaf extract,” “alloxan-induced diabetes,” and “blood glucose.” From 472 identified articles, 9 studies met inclusion criteria and were analyzed. Results: Nearly all studies reported significant reductions in blood glucose levels following administration of Moringa oleifera leaf extracts at effective doses ranging from 200–800 mg/kg body weight over 14–28 days. Key mechanisms include protection of pancreatic β-cells from oxidative stress, enhanced insulin secretion, and improved insulin sensitivity. Both aqueous and ethanolic extracts exhibited antihyperglycemic effects, with aqueous extracts demonstrating faster onset and ethanolic extracts providing more sustained outcomes. Conclusion: These findings support the potential of Moringa oleifera leaf extracts as a natural antidiabetic agent in preclinical models. However, further research is required to standardize extraction methods, dosages, and molecular mechanisms to facilitate clinical translation in humans.

Page 1 of 1 | Total Record : 4

 1 

Filter by Year

2025 2025


Reset
Filter By Issues
All Issue Vol. 4 No. 12 (2025): December Vol. 4 No. 11 (2025): November Vol. 4 No. 10 (2025): October Vol. 4 No. 9 (2025): September Vol. 4 No. 8 (2025): August Vol. 4 No. 7 (2025): July Vol. 4 No. 6 (2025): June Vol. 4 No. 5 (2025): May Vol. 4 No. 4 (2025): April Vol. 4 No. 3 (2025): March Vol. 4 No. 2 (2025): February Vol. 4 No. 1 (2025): January Vol. 3 No. 12 (2024): December Vol. 3 No. 11 (2024): November Vol. 3 No. 10 (2024): Oktober Vol. 3 No. 9 (2024): September Vol. 3 No. 8 (2024): August Vol. 3 No. 7 (2024): July Vol. 3 No. 6 (2024): June Vol. 3 No. 5 (2024): May Vol. 3 No. 4 (2024): April Vol. 3 No. 3 (2024): March Vol. 3 No. 2 (2024): February Vol. 3 No. 1 (2024): January Vol. 2 No. 12 (2023): December Vol. 2 No. 11 (2023): November Vol. 2 No. 10 (2023): October Vol. 2 No. 9 (2023): September Vol. 2 No. 8 (2023): August Vol. 2 No. 7 (2023): July Vol. 2 No. 6 (2023): June Vol. 2 No. 5 (2023): May Vol. 2 No. 4 (2023): April Vol. 2 No. 3 (2023): March Vol. 2 No. 2 (2023): February Vol. 2 No. 1 (2023): January Vol. 1 No. 3 (2022): December Vol. 1 No. 2 (2022): November Vol. 1 No. 1 (2022): October More Issue